H. Lundbeck A/S
HLUN-A
Ранг среди акций
#3031
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Цена акции
$7.16
Последняя синхронизация: 2026-10-19
Рыночная капитализация
$6.03B
Изменение (1 день)
0.22%
Изменение (1 год)
29.19%
Страна
DK
Торговля H. Lundbeck A/S (HLUN-A)
Категория
Healthcare
Операционная маржа для H. Lundbeck A/S (HLUN-A)
Операционная маржа на October 2026 TTM: 27.21%
Согласно последним финансовым отчетам и цене акций H. Lundbeck A/S, текущая операционная маржа (TTM) составляет 27.21%. В конце 2024 она составила 14.86%.
История операционной маржи H. Lundbeck A/S с 2004 по 2026
Операционная маржа на конец каждого года
| Год | Операционная маржа | Изменить |
|---|---|---|
| 2026 (TTM) | 27.21% | 4.45% |
| 2025 | 26.05% | 75.30% |
| 2024 | 14.86% | -7.41% |
| 2023 | 16.05% | 2.69% |
| 2022 | 15.63% | 26.76% |
| 2021 | 12.33% | 9.50% |
| 2020 | 11.26% | -45.84% |
| 2019 | 20.79% | -29.91% |
| 2018 | 29.66% | 15.95% |
| 2017 | 25.58% | 74.49% |
| 2016 | 14.66% | -132.77% |
| 2015 | -44.73% | -6,144.59% |
| 2014 | 0.74% | -92.94% |
| 2013 | 10.48% | -5.84% |
| 2012 | 11.13% | -47.50% |
| 2011 | 21.20% | -6.77% |
| 2010 | 22.74% | 9.38% |
| 2009 | 20.79% | -0.24% |
| 2008 | 20.84% | -15.08% |
| 2007 | 24.54% | 26.82% |
| 2006 | 19.35% | -19.11% |
| 2005 | 23.92% | -8.84% |
| 2004 | 26.24% | 0.00% |
Операционная маржа для аналогичных компаний или конкурентов
| Компания | Операционная маржа | Разница в операционной марже | Страна |
|---|---|---|---|
| 62.34% | -97.71% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 29.76% | -98.91% |
HK
|
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.